stockrowAbbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- +28.9%
- Total debt
- +140.8%
Quarter to September 2026, against a year earlier
Follow ABT
Alert me
Abbott Laboratories (ABT) Return on equity
Abbott Laboratories's return on equity over the twelve months to 30 September 2026 was 9.14%, down 3.8 percentage points from fiscal 2025 (13.0%). Over the past ten years it has ranged from 1.84% (fiscal 2017) to 30.9% (fiscal 2024); the current reading is higher than 45% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 13.0% | (17.95) |
| FY2024 | 30.9% | 15.80 |
| FY2023 | 15.1% | (3.90) |
| FY2022 | 19.0% | (1.48) |
| FY2021 | 20.5% | 6.51 |
| FY2020 | 14.0% | 2.09 |
| FY2019 | 11.9% | 4.23 |
| FY2018 | 7.66% | 5.82 |
| FY2017 | 1.84% | (4.82) |
| FY2016 | 6.66% | (13.93) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| DXCM DexCom, Inc. compare | 37.7% |
| GEHC GE HealthCare Technologies Inc. compare | 19.9% |
| SYK Stryker Corporation compare | 16.0% |
| BSX Boston Scientific Corporation compare | 14.2% |
| STE STERIS plc compare | 11.6% |
| MDT Medtronic PLC compare | 10.6% |
| EW Edwards Lifesciences Corporation compare | 9.65% |
| PHG Koninklijke Philips N.V. compare | 8.54% |
| ABT Abbott Laboratories | 0.00% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ABT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement